Effects of UR-12633, a new antagonist of platelet-activating factor, in rodent models of endotoxic shock

British Journal of Pharmacology

Volumn 118, Issue 5, 1996, Pages 1223-1231

  Giral, Marta ^a   Balsa, Dolors ^a   Ferrando, Rosa ^a   Merlos, Manuel ^a   Garcia Rafanell, Julian ^a   Forn, Javier ^a  

^a Grupo Uriach   (Spain)

Author keywords

Disseminated intravascular coagulation; Endotoxic shock; Haemoconcentration; Hyperglycaemia; Hyperlactacidaemia; Platelet activating factor; UR 12633; WEB 2086

Indexed keywords

ACID PHOSPHATASE; APAFANT; ESCHERICHIA COLI LIPOPOLYSACCHARIDE; EVANS BLUE; FIBRINOGEN; LACTATE DEHYDROGENASE; PIPERIDINE DERIVATIVE; THROMBOCYTE ACTIVATING FACTOR ANTAGONIST; UNCLASSIFIED DRUG; UR 12633;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD VESSEL PERMEABILITY; CONTROLLED STUDY; DISSEMINATED INTRAVASCULAR CLOTTING; DRUG STRUCTURE; ENZYME ACTIVITY; EXTRAVASATION; FIBRINOGEN BLOOD LEVEL; HYPERGLYCEMIA; HYPERLACTATEMIA; HYPOTENSION; INTRAVENOUS DRUG ADMINISTRATION; LYSOSOME; MALE; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; RAT; SEPTIC SHOCK; THROMBOCYTE AGGREGATION INHIBITION; TISSUE INJURY;

EID: 0030036625     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1476-5381.1996.tb15527.x     Document Type: Article

References (39)

1. BALSA, D., MERLOS, M., GIRAL, M., GARCIA-RAFANELL, J. & FORN, J. (1993). Tissue distribution of increased vascular permeability and gastric damage induced by endotoxin in rats: effect of PAF antagonists. World Congress Inflammation '93. Vienna Austria, p.84.
2. BRADFORD, M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal. Biochem., 72, 248-254.
3. BRECHT, H.M., ADAMUS, W.S., HEUER, H.O., BIRKE, F.W. & KEMPE, E.R. (1991). Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man. Arzneim. Forsch., 41, 51-59.
4. CHANG, S.-W., FEDDERSEN, CO., HENSON, P.M. & VOELKEL, N.F. (1987). Platelet-activating factor mediates hemodynamic changes and lung injury in endotoxin-treated rats. J. Clin. Invest., 79, 1498-1509.
5. DANNER, R.L., ELIN, R.J., HOSSEINI, J.M., WESLEY, R.A., REILLY, J.M. & PARRILLO. J.E. (1991). Endotoxemia in human septic shock. Chest, 99, 169-175.
6. DEJOY, S.O., ORONSKY, A.L., WICK, M.M. & KERWAR, S.S. (1993). Preclinical studies with platelet-activating factor antagonists in models of septic shock. Int. J. Antimicrob. Agents, 3, 175-186.
7. DOEBBER, T.W., WU, M.S., ROBBINS, J.C., CHOY, B.M., CHANG, M.N. & SHEN, T.Y. (1985). Platelet activating factor (PAF) involvement in endotoxin-induced hypotension in rats. Studies with PAF-receptor antagonist kadsurenone. Biochem. Biophys. Res. Commun., 127, 799-808.
8. EMEIS, J.J. & KLUFT, C. (1985). PAF-acether-induced release of tissue-type plasminogen activator from vessel walls. Blood, 66, 86-91.
9. EVANS, T.W., DENT, G., ROGERS, D.T., AURSUDKIJ, B., CHUNG, K.F. & BARNES, P.J. (1988). Effects of a PAF antagonist, WEB-2086, on airway microvascular leakage in the guinea pig and platelet aggregation in man. Br. J. Pharmacol., 94, 164-168.
10. FLEMING, L. DAMBACHER, T. & BUSSE, R. (1992). Endothelium-derived kinins account for the immediate response of endothelial cells to bacterial lipopolysaccharide. J. Cardiovasc. Pharmacol., 20, S135-S138.
11. FLOCH, A., MASSA, N. & CAVERO, I. (1990). Studies on the pharmacological mechanisms responsible for the hemoconcentration produced by PAF an endotoxin in rats. In Platelet Activating Factor in Endotoxin and Immune Diseases. ed. Handley, D.A., Saunders, R.N., Houlihan, W.J. & Tomesch, J.C. pp. 577-588, New York: Marcel Dekker.
12. HARLAN, J.M., HARKER, L.A., REIDY, M.A., GAJDUSEK, C.M., SCHWARTZ, S.M. & STRIKER, G.E. (1983). Lipopolysaccharide-mediated bovine endothelial cell injury in vitro. Lab. Invest., 48, 269-274.
13. HOSFORD, D.J., DOMINGO, M.T., CHABRIER, P.E. & BRAQUET, P. (1990). Ginkgolides and platelet-activating factor. Methods Enzymol., 187, 433-447.
14. HURLEY, J.C. (1993). Reappraisal of the role of endotoxin in the sepsis syndrome. Lancet, 341, 1133-1135.
15. IKEGAMI, K., MEADE, C.J., HEUER, H.O. & BIRKE, F. (1992). Hetrazepine PAF antagonists. J. Lipid Med., 5, 177-182.
16. IMURA, Y., TERASHITA, Z. & NISHIKAWA, K. (1986). Possible role of platelet activating factor (PAF) in disseminated intravascular coagulation (DIC), evidenced by use of a PAF antagonist, CV-3988. Life Sci., 39, 111-117.
17. INARREA, P., GOMEZ-CAMBRONERO, J., NIETO, M. & SANCHEZ CRESPO, M. (1984). Characteristics of the binding of platelet-activating factor to platelets of different animal species. Eur. J. Pharmacol., 105, 309-315.
18. KATORI, M., MAJIMA, M., ODOI-ADOME, R., SUNAHARA, N. & UCHIDA, Y. (1989). Evidence for the involvement of a plasma kallikrein-kinin system in the immediate hypotension produced by endotoxin in anaesthetized rats. Br. J. Pharmacol., 98, 1383-1391.
19. KAWAMURA, M., TERASHITA, Z., IMURA, Y., SHINO, A. & NISHIKAWA, K. (1993). Inhibitory effect of TCV-309, a novel platelet activating factor (PAF) antagonist, on endoloxin induced disseminated intravascular coagulation in rats: possible role of PAF in tissue factor generation. Thromb. Res., 70, 281-293.
20. KOLTAI, M., HOSFORD, D., GUINOT, P., ESANU, A. & BRAQUET, P. (1991a). PAF, a review of its effects, antagonists and possible future implications (Part I). Drugs. 42, 9-29.
21. KOLTAI, M., HOSFORD, D., GUINOT, P., ESANU, A. & BRAQUET, P. (1991b). PAF, a review of its effects, antagonists and possible future implications (Part II). Drugs. 42, 174-204.
22. LANG, C.H. & BAGBY, G.J. (1990). The role of platelet-activating factor in endotoxin-, sepsis-, and burn-induced changes in hemodynamics and metabolism. In Platelet Activating Factor in Endotoxin and Immune Diseases. ed. Handley. D.A., Saunders, R.N., Houlihan, W.J. & Tomesch, J.C. pp. 609-628, New York: Marcel Dekker.
23. LANG, C.H., DOBRESCU, C., HARGROVE, D.M., BAGBY. G.J. & SPITZER, J.J. (1988). Platelet-activating factor-induced increases in glucose kinetics. Am. J. Physiol., 254, E193-F200.
24. MCCABE, W.R. & OLANS, R.N. (1981). Shock in Gram-negative bacteremia: Predisposing factors, pathophysiology, and treatment. In Current Clinical Topics in Infectious Diseases. Vol. 2. ed. Remington, J.S., Swartz, M.N. pp. 121-150. New York: McGraw-Hill.
25. MEYRICK, B.O., RYAN, U.S. & BRIGHAM, K.L. (1986). Direct effects of E. coli endotoxin on structure and permeability of pulmonary endothelial monolayers and the endothelial layer of intimai explants. Am. J. Pathol., 122, 140-151.
26. MORRISON, D.C. & RYAN, J.L. (1987). Endotoxins and disease mechanisms. Annu. Rev. Med., 38, 417-432.
27. PARRILLO, J.E. (1993). Pathogenetic mechanisms of septic shock. N. Engl. J. Med., 328, 1471-1477.
28. QI, M. & JONES, S.B. (1990). Contribution of platelet activating factor to hemodynamic and sympathetic responses to bacterial endotoxin in conscious rats. Circ. Shock, 32, 153-163.
29. RABINOVICI, R., ESSER, K.M., LYSKO, P.G., YUE, T., GRISWOLD, D.E., HILLEGASS, L.M., BUGELSKI, P.J., HALLENBECK, J.M. & FEUERSTEIN, G. (1991). Priming by platelet-activating factor of endotoxin-induced lung injury and cardiovascular shock. Circ. Res., 69, 12-25.
30. 3H]apafant, a selective and competitive platelet-activating factor antagonist: evidence that the noncompetitive behavior of apafant in functional studies relates to slow kinetics of dissociation. Mol. Pharmacol., 43, 302-312.
31. RYLANDER, R. & BEIJER, L. (1987). Inhalation of endotoxin stimulates alveolar macrophage production of platelet activating factor. Am. Rev. Respir. Dis., 135, 83-86.
32. SZABO, C., MITCHELL, J.A., THIEMERMANN, C. & VANE, J.R. (1993a). Nitric oxide-mediated hyporeactivity to noradrenaline precedes the induction of nitric oxide synthase in endotoxic shock. Br. J. Pharmacol., 108, 786-792.
33. SZABÓ, C., WU, C.C., MITCHELL, J.A., GROSS, S.S., THIEMERMANN, C. & VANE, J.R. (1993b). Platelet-activating factor contributes to the induction of nitric oxide synthase by bacterial lipopolysaccharide. Circ. Res., 73, 991-999.
34. TALLARIDA, R.J. & MURRAY, R.B. (1981). Procedure 8: Graded Dose-Response. In Manual of Pharmacologic Calculations. pp 14-19. New York: Spriger-Verlag.
35. TAVEIRA DA SILVA, A.M., KAULBACH, H.C., CHUIDIAN, F.S., LAMBERT, D.R., SUFFREDINI, A.F. & DANNER, R.L. (1993). Brief report: shock and multiple-organ dysfunction after self-administration of Salmonella endotoxin. N. Engl. J. Med., 328, 1457-1460.
36. THOMPSON, W.A., COYLE, S., KIMBERLY, V.Z., OLDENBURG, H., TROUSDALE, R., ROGY, M., FELSEN, D., MOLDAWER, L. & LOWRY, S.F. (1994). The metabolic effects of platelet-activating factor antagonism in endotoxemic man. Arch. Surg., 129, 72-79.
37. TOTH, P.D. (1990). The biological effects of PAF antagonists in endotoxemia. In Platelet Activating Factor in Endotoxin and Immune Diseases, ed. Handley, D.A., Saunders, R.N., Houlihan. W.J. & Tomesch, J.C. pp. 589-608, New York: Marcel Dekker.
38. VAN DEVENTER, S.J.H., BULLER, H.R., TEN CATE, J.W., AARDEN. L.A., HACK, C.E. & STURK, A (1990). Experimental endotoxemia in humans: analysis of cytokine release and coagulation, fibrinolitic and complement pathways. Blood. 76, 2520-2526.
39. WHITTLE, B.J.R., BOUGHTON-SMITH, N.K., HUTCHESON, I.E., ESPLUGUES, J.V. & WALLACE, J.L. (1987). Increased intestinal formation of PAF in endotoxin-induced damage in the rat. Br. J. Pharmacol., 92, 3-4.